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Arsenic as a Human
Carcinogen
Chronic arsenic exposure is of concern
mainly because of its carcinogenic effects.
Evidence for arsenic as a human carcinogen
comes from studies of lung cancer in ore
smelters, and of skin, lung, and bladder can-
cers in people exposed to drinking water con-
taining arsenic or exposed therapeutically to
Fowler’s solution (potassium arsenite). The
increase in cancer risk observed in epidemio-
logic studies is attributed mainly to the pres-
ence of inorganic trivalent arsenic (1,2). 
Arsenic is the most extensively studied of
the metals and metalloids found in drinking
water. The association between skin cancer
and arsenic ingestion in drinking water was
seen in studies in Taiwan, Chile, Argentina,
and Mexico (3–7). Bates et al. (8) reviewed
studies on arsenic ingestion and internal can-
cers and found that many studies were unin-
formative because of low statistical power or
potential bias either in collection or analysis
of data. However, all studies in the Taiwan
area found an association with increased
lung cancer risk (9). Analysis of a Japanese
population exposed to arsenic in drinking
water also found an association with
increased lung cancer risk, but in addition
found evidence of strong synergy between
smoking and arsenic ingestion (10). Similar
results were seen in a Taiwan population
(11) where there was no increased risk in
nonsmokers but a risk ratio of 2.45 in smok-
ers in the arsenic-endemic area. In a recent
review, Hertz-Piccioto (12) calculates that
the synergistic excess fraction of lung cancer
(i.e., the proportion of cases among those
with two exposures that would not have
occurred had only one of the exposures been
present) ranges from 30 to 54% for smoking
and industrial exposure to arsenic. 
Ultraviolet radiation (UVR) from sun-
light is the most prominent carcinogen in our
natural environment and the most important
cause of skin cancers (13). For reasons that
become evident below, we hypothesize that
just as tobacco smoke synergizes with arsenic
in causing lung cancer, so too does UVR syn-
ergize with arsenic in causing skin cancer.
This is not meant to rule out possible synergy
with other causes of skin cancer, such as ion-
izing radiation, cigarette smoke, other envi-
ronmental polycyclic aromatic hydrocarbons,
and papillomavirus (14–17). 
Problems in Finding an
Animal Model for Arsenic
Carcinogenesis
Because of the lack of a good animal model,
arsenic compounds are the only compounds
that the International Agency for Research
on Cancer (IARC) considers to have suffi-
cient evidence for human carcinogenicity
but inadequate evidence for animal carcino-
genicity (18). The review of arsenic carcino-
genicity by IARC (1) lists four different
species (mouse, rat, dog, rabbit) given vari-
ous arsenic compounds by different routes of
exposure. There was no consistent demon-
stration of arsenic carcinogenicity in these
studies. A few reports of arsenic-induced car-
cinogenesis exist. When rats were treated by
intratracheal instillation with a vineyard pes-
ticide containing calcium arsenate, 10 of 25
rats died. Of the 15 surviving rats, 9 devel-
oped lung carcinoma. However, most of the
tumors were very small and could only be
detected microscopically, and parts of the
lung were severely damaged (19). Similar
results were observed in hamsters (20).
Pershagen et al. (21) applied carrier dust
(charcoal carbon) for longer lung retention
of arsenic trioxide and other chemicals to
mimic the situation encountered in smelter
workroom air, with some success. Despite
these positive results, it must be kept in
mind that very toxic doses of arsenic com-
pounds were required for tumor induction.
All published reports attempting to induce
tumors with arsenic in drinking water have
given negative results (22).
Because arsenite is not signiﬁcantly muta-
genic in bacterial or mammalian cells at con-
centrations giving high levels of survival (see
below), it is sometimes assumed that arsenite
must be a tumor promoter. There is little evi-
dence for this view, as negative results have
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Although epidemiologic evidence shows an association between inorganic arsenic in drinking
water and increased risk of skin, lung, and bladder cancers, no animal model for arsenic carcino-
genesis has been successful. This lack has hindered mechanistic studies of arsenic carcinogenesis.
Previously, we and others found that low concentrations (≤5 µm) of arsenite (the likely environ-
mental carcinogen), which are not mutagenic, can enhance the mutagenicity of other agents,
including ultraviolet radiation (UVR) and alkylating agents. This enhancing effect appears to
result from inhibition of DNA repair by arsenite, but not via inhibition of DNA repair enzymes.
Rather, low concentrations of arsenite disrupt p53 function and upregulate cyclin D1. Failure to
ﬁnd an animal model for arsenic carcinogenesis might be because arsenite is not a carcinogen per
se but acts as an enhancing agent (cocarcinogen) with a genotoxic partner. We tested this
hypothesis with solar UVR in hairless but immunocompetent Skh1 mice. Mice were given 10
mg/L sodium arsenite in drinking water (or not) and irradiated with 1.7 KJ/m2 solar UVR 3
times weekly. As expected, no tumors appeared in any organs in control mice or in mice given
arsenite alone. After 26 weeks irradiated mice given arsenite had a 2.4-fold increase in skin tumor
yield compared with mice given UVR alone. The tumors were mostly squamous cell carcinomas,
and those occurring in mice given UVR plus arsenite were much larger and more invasive. These
results are consistent with the hypothesis that arsenic acts as a cocarcinogen with a second (geno-
toxic) agent by inhibiting DNA repair and/or enhancing positive growth signaling. Skin cancers
in populations drinking water containing arsenic may be caused by the enhancement by arsenic
compounds of carcinogenesis induced by UVR (or other environmental agents). It is possible
that lung and bladder cancers associated with arsenic in drinking water may also require a car-
cinogenic partner. Key words: arsenic, carcinogenesis, cocarcinogen, DNA repair, genotoxicity,
proliferation, ultraviolet light. Environ Health Perspect 110(suppl 5):749–752 (2002).
http://ehpnet1.niehs.nih.gov/docs/2002/suppl-5/749-752rossman/abstract.html
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been obtained in bioassays testing arsenite for
promotional activity (23,24). Arsenic com-
pounds were also not carcinogenic to animals
when tested at reasonable doses as initiators




Unlike many carcinogens, arsenite is not a
mutagen except weakly at high (toxic) con-
centrations in Escherichia coli or Chinese
hamster V79 cells (25,26). Attempts have
been made to find genetic markers more
likely to detect large deletions. In transgenic
G12 cells assayed at the E. coli gpt locus,
which can detect clastogens causing dele-
tions (27), and in mouse lymphoma cells,
which can tolerate deletions at the TK
locus, weak effects are also seen at toxic
doses (28,29). This is also true in AL cells
(CHO-K1 cells containing a single copy of
human chromosome 11), which can suffer
deletions (30). 
Arsenite does, however, induce chromo-
some aberrations, aneuploidys, and micro-
nuclei (a marker of chromosome damage) in
cultured cells (31). Micronuclei are found in
the bone marrow of mice treated with arsen-
ite (2) and in exfoliated bladder cells from
exposed humans (32). Arsenite caused gene
amplification at the dhfr locus in SV40-
transformed human keratinocytes but failed
to cause ampliﬁcation of the SV40 sequences
(33). This ﬁnding suggests that arsenite does
not induce signaling typical of DNA-damag-
ing agents (which induce SV40 amplifica-
tion in this system), but rather might affect
checkpoint pathways such as those involving
p53, whose disruption leads to cellular gene
ampliﬁcation (34).
Arsenite can induce transformation to a
more malignant phenotype in Syrian hamster
embryo cells, BALB/3T3 mouse embryo
cells, and 10T1/2 mouse embryo cells
(31,35,36). Arsenite also caused anchorage-
independent growth, a marker of transforma-
tion, but no focus formation or immortality
in diploid human ﬁbroblasts (37). We have
found that human osteosarcoma cells can be
transformed to anchorage independence by
exposure to low concentrations of arsenite for
8 weeks but not for 2 weeks (35). The mech-
anism of arsenite’s ability to transform cells is
not known.
Arsenite enhances the mutagenicity of
ultraviolet C light (UVC) (28), which causes
DNA lesions repairable by nucleotide
excision repair, as well as N-methyl-N-
nitrosourea (MNU) (26), which causes
DNA adducts repairable by base excision
repair, in V79 cells. This suggests that arsen-
ite might inhibit a late step in DNA repair
shared by both DNA repair pathways. (V79
cells lack O6-methylguanine DNA methyl-
transferase, so all premutagenic MNU
adducts would be subject to base excision
repair.) An assay for DNA strand breaks or
gaps showed that in cells treated with MNU
plus arsenite, breaks remained open 3 hr
after MNU treatment, whereas in the
absence of arsenite, the breaks had closed by
that time (26). This suggested that either the
polymerase or the ligase step of base excision
repair had been blocked by arsenite. 
In subsequent experiments nuclear
extracts of cells treated with arsenite
decreased nuclear ligase activity, particularly
of the enzyme now called DNA ligase III
(previously called DNA ligase II) (38).
Treatment of cells with MNU resulted in a
robust activation of DNA ligase III activity
after 3 hr, the mechanism of which is still
unknown. This activation was blocked by
cotreatment of cells with arsenite, and in fact
a 50% inhibition of ligase activity was seen
even in control cells. However, when arsen-
ite was added to nuclear extract from
untreated cells, inhibition occurred only at
concentrations of arsenite 1,000-fold higher
than those seen after cellular exposure to
arsenite, indicating that arsenite does not
directly inhibit DNA ligase activity (38).
This was recently confirmed using purified
DNA ligase III (39). Further support was
found in experiments using single-cell alka-
line electrophoresis (comet assay). Treatment
of cells with arsenite inhibited DNA strand
break rejoining, which was also attributed
primarily to inhibition of DNA ligase III by
using a ligase III–specific substrate (40). In
addition, DNA polymerases α and β are not
sensitive to inhibition by arsenite. DNA
polymerase β , in fact, is stimulated by arsen-
ite concentrations up to at least 12 mM,
and DNA polymerase α requires >1 mM
arsenite for inhibition (39,41). Our hypoth-
esis was that arsenite downregulates control
of DNA repair rather than inhibiting DNA
repair enzymes. 
In a test of this hypothesis, we recently
showed that in cells treated with arsenite
and ionizing radiation, the p53-dependent
increase in p21 expression, normally a block
to cell cycle progression after DNA damage,
is deﬁcient (42). This is expected to lead to
faulty DNA repair. In addition, we and oth-
ers have found that low (nontoxic) exposure
to arsenite enhances positive growth signal-
ing (24,42–46). We suggest that the
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Table 1. Tumors appearing in mice given UVR alone or UVR plus arsenite.
Tumor Tumor type
Mouse number SCC(HI) SCC(MI) KIN Fib Pap Hyp
UVR alone
14 1  2 1
24 1 3  
32 1 1
44 2 1 1
52 1 1
62 1 1
76 1 2 3  
83 1 2
95 2 2 1
10 2 1 1
11 6 2 3 1
12 5 3 2
13 2 2
14 3 1 1 1
15 3 1 2
Total (%)  53 14 (26.4) 26 (49.1) 10 (18.9) 1 (1.9) 2 (3.8) 0 (0)
UVR plus arsenite
19 5  2 2
23 2 1
33 1 1 1
46 5 1
51 9 1 0 3 3 111
66 4 1 1
78 3 3 2
85 2 2 1
91 5 9 5 1
10 12 7 3 2
11 3 1 1 1
12 9 2 4 2 1
13 8 4 4
14 12 5 4 2 1
15 9 4 3 2
Total (%) 127 64 (50.4) 38 (29.9) 16 (12.6) 1 (0.79) 4 (3.1) 4 (3.1)
Abbreviations: Fib, fibrosarcoma; Hyp, hyperplasia; KIN, keratinocytic intraepidermal neoplasia; Pap, papilloma;
SCC(HI), squamous cell carcinoma (highly invasive); SCC(MI), squamous cell carcinoma (minimally invasive).Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 751
absence of normal p53 functioning and
increased positive growth signaling in the
presence of DNA damage both contribute
to defective DNA repair and account for the
comutagenic effects of arsenite. 
Arsenic as a Cocarcinogen
Based on our understanding of the genetic
toxicology of arsenic, we have developed a
new mouse model for arsenic carcinogenesis
that combines a nontoxic concentration of
sodium arsenite in drinking water with a low
(nonerythemic) dose of solar ultraviolet radi-
ation (UVR) (36). Skh1 (hairless but
immunocompetent) mice given 10 mg/L
arsenite (equivalent to ∼ 5,770 ppb arsenic) in
drinking water for 26 weeks had a 2.4-fold
increase in yield of tumors after 1.7 KJ/m2
solar UVR 3 times weekly compared with
mice given UVR alone (Table 1). The
tumors on mice receiving arsenite plus UVR
were more highly invasive than those receiv-
ing UVR alone (p < 0.01 by Fisher’s exact
test). This concentration of arsenite had no
effect on weight gain, appearance, health, or
activity of the mice. As expected, no tumors
appeared in any organs of mice given arsenite
alone. Tumors appeared only in mice that
had received UVR, and only on the exposed
area (backs) of the mice. The tumors were
mostly squamous cell carcinomas; those
occurring in mice given UVR plus arsenite
appeared earlier (Figure 1) and were much
larger than in mice given UVR alone (35,36). 
Mutations of the tumor suppressor p53
gene are the most frequent genetic abnormal-
ity seen in human cancers and occur in up to
90% of squamous cell carcinomas (depend-
ing on the study) (47,48). P53 protein
inhibits cellular progression through the cell
cycle in response to DNA damage. If dam-
aged DNA were to be replicated, it could be
mutated or lost because of chromosome
breaks. Evidence suggests that p53 mutations
are an early event in skin cancer (47).
Transgenic mice null for p53 are at increased
risk of chemical carcinogen–induced skin
tumors (49). Arsenite in drinking water may
have an effect similar to p53 mutation by
preventing normal p53 function.
This is the first demonstration that low
concentrations of arsenite can enhance the
onset and growth of malignant skin tumors
induced by a genotoxic carcinogen in mice
(36). It should be noted that the concentra-
tion of sodium arsenite used in the drinking
water corresponds to approximately 5,770
µg/L arsenic. This is >100 times the cur-
rently allowable level in drinking water in
the United States. It is about 4.4 times
higher than the highest concentration
(1,300 µg/L) found in Nevada drinking
water (32) and only 1.7 times higher than
the highest concentrations (3,400 µg/L)
found in drinking water in the West Bengal
region of India (50). It is of great impor-
tance to perform dose–response experiments
on the cocarcinogenic effects of arsenite in
drinking water to establish the shape of the
dose–response curve and to determine
whether a threshold exists.
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Figure 1. Time to first tumor. Fifteen female Skh1
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UVB) alone or solar UVR plus arsenite in drinking
water according to the protocol in Rossman et al.
(36). Results are expressed as the time after start
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